Using Machine Learning Algorithms to Predict Hepatitis B Surface Antigen Seroclearance

Table 1

Summary of participant’s characteristics.

Variables	Value
Age (years)^a	40.58 ± 12.07
Gender (male)^b	1636 (73.2)
BMI^a	22.53 ± 3.96
Drinking history^b	256 (11.5)
HBV family history^b	1350 (60.4)
HCC family history^b	188 (8.4)
Initial diagnosis^b
Inactive hepatitis B virus carrier	12 (0.5)
Chronic hepatitis B	1966 (88.0)
Hepatitis cirrhosis	216 (9.7)
Hepatocellular carcinoma	41 (1.8)
Current diagnosis^b
Hepatitis B virus carrier	13 (0.5)
Chronic hepatitis B	1875 (83.9)
Hepatitis cirrhosis	222 (9.9)
Hepatocellular carcinoma	125 (5.6)
ALT^a (U/L)	95.91 ± 167.82
AST^a (U/L)	144.68 ± 280.77
GGT^a (U/L)	59.32 ± 79.35
PLT^a (U/L)	175.19 ± 67.53
ALB^a (g/L)	44.61 ± 5.37
TBIL^a (μmol/L)	25.40 ± 52.83
DBIL^a (μmol/L)	11.17 ± 41.19
PLT^a (×10^9/L)	175.19 ± 67.53
DNA^a (log/IU/mL)	5.57 ± 2.05
sAg^a (log/IU/mL)	3.42 ± 0.81
eAg^a (log/IU/mL)	0.71 ± 1.63
WBC^a (×10^9/L)	6.03 ± 1.93
HB^a (g/L)	140.66 ± 34.48
RLOD^a (mm)	114.85 ± 27.92
PVW^a (mm)	11.37 ± 4.17
SL^a (mm)	102.74 ± 21.19
SPVW^a (mm)	6.17 ± 4.39
Initial treatment^b
None	874 (39.1)
LMV	248 (11.1)
ADV	277 (12.4)
LdT	111 (5.0)
ETV	610 (27.3)
TDF	62 (2.8)
LMV + ADV	47 (2.1)
LdT + ADV	4 (0.2)
ETV + ADV	2 (0.1)
Lines^b
0	1035 (46.3)
1	818 (36.6)
2	211 (9.4)
3	93 (4.2)
4	46 (2.1)
5	18 (0.8)
6	10 (0.5)
7	1 (0.0)
8	2 (0.1)
9	1 (0.0)
Current treatment^b
None	1019 (45.6)
LMV	68 (3.0)
ADV	152 (6.8)
LdT	26 (1.2)
ETV	61 (27.4)
TDF	252 (11.3)
LMV + ADV	79 (3.5)
LdT + ADV	6 (0.3)
ETV + ADV	21 (0.9)
IFN^b	115 (5.1)
VR^b
IVR	332 (14.9)
EVR	976 (43.7)
SOR	976 (41.5)

^aMean and standard deviation; ^bfrequencies and percentages; VR: virological response; IVR: initial virological response; EVR: early virological response; SOR: suboptimal virological response.